Zura Bio (ZURA) and Its Peers Financial Survey

Zura Bio (NASDAQ:ZURA) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Zura Bio to similar businesses based on the strength of its institutional ownership, risk, profitability, dividends, analyst recommendations, valuation and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Zura Bio and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	0	1	6	1	3.00
Zura Bio Competitors	1924	5381	13923	296	2.58

Zura Bio currently has a consensus target price of $15.00, indicating a potential upside of 1,085.77%. As a group, “Biological products, except diagnostic” companies have a potential upside of 102.96%. Given Zura Bio’s stronger consensus rating and higher probable upside, research analysts clearly believe Zura Bio is more favorable than its competitors.

Volatility and Risk

Zura Bio has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, Zura Bio’s competitors have a beta of -3.86, indicating that their average share price is 486% less volatile than the S&P 500.

Institutional and Insider Ownership

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 22.1% of Zura Bio shares are owned by insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Zura Bio and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zura Bio	N/A	-$69.24 million	-2.39
Zura Bio Competitors	$574.62 million	-$70.96 million	-0.15

Zura Bio’s competitors have higher revenue, but lower earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Zura Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-37.36%	-29.81%
Zura Bio Competitors	-2,185.76%	-161.46%	-40.62%

Summary

Zura Bio beats its competitors on 11 of the 13 factors compared.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.